GALNT15
Polypeptide N-Acetylgalactosaminyltransferase 15
Gene Information Card
| Symbol | GALNT15 |
|---|---|
| Full Name | Polypeptide N-Acetylgalactosaminyltransferase 15 |
| Gene Type | Protein coding |
| Chromosomal Location | 3q13.13 |
| NCBI Gene ID | 117248 ncbi.nlm.nih.gov/gene/117248 |
| Ensembl ID | ENSG00000163823 |
| UniProt ID | Q8N3T6 |
| OMIM ID | 615220 |
| HGNC ID | 23247 |
| Aliases | GALNT15, GalNAc-T15, pp-GalNAc-T15 |
Description
GALNT15 encodes a member of the UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T) family, which initiates mucin-type O-linked glycosylation in the Golgi apparatus. This enzyme transfers N-acetylgalactosamine (GalNAc) to serine and threonine residues on target proteins. GALNT15 is involved in protein glycosylation and may play roles in cell adhesion, signaling, and cancer progression.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Colorectal cancer | Altered glycosylation patterns due to GALNT15 expression changes may affect tumor cell adhesion and metastasis. | COSMIC; literature (PMID: 25691885) |
| Pancreatic cancer | Differential expression of GALNT15 is associated with tumor progression and poor prognosis. | COSMIC; literature (PMID: 28708995) |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Kidney | 12.5 | Medium |
| Liver | 8.3 | Medium |
| Testis | 6.7 | Low |
| Colon | 5.1 | Low |
| Pancreas | 4.9 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK 293 | 15.2 | Embryonic kidney cells |
| HepG2 | 10.1 | Hepatocellular carcinoma cells |
| MCF7 | 3.4 | Breast cancer cells |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1045G>A (p.Gly349Arg) | Missense | <0.01% | Unknown functional impact |
| c.1573C>T (p.Arg525Trp) | Missense | <0.01% | Unknown functional impact |
Mutation functional classification
Loss of Function (LOF)
No confirmed loss-of-function mutations reported in ClinVar or COSMIC.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported.
Dominant Negative (DN)
No evidence for dominant-negative effects.
View complete mutation data：
Gene Ontology (GO)
| • polypeptide N-acetylgalactosaminyltransferase activity (GO:0004653) | • protein O-linked glycosylation (GO:0006493) |
| • Golgi apparatus (GO:0005794) | • integral component of membrane (GO:0016021) |
Pathways
• O-linked glycosylation of mucins (Reactome: R-HSA-913709)
Protein Summary
GALNT15 is a type II transmembrane protein localized to the Golgi apparatus. It catalyzes the initial step of mucin-type O-glycosylation, transferring GalNAc from UDP-GalNAc to serine/threonine residues. The protein contains a catalytic domain and a lectin domain that may facilitate substrate recognition. Its expression is tissue-specific and altered in certain cancers.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| GALNT15 Knockout HEK293 Cell Line | EDJ-KQ7603 | Human | 117248 | Details Get a Quote |
| GALNT15 Knockout HeLa Cell Line | EDJ-KQ58013 | Human | 117248 | Details Get a Quote |
| GALNT15 Knockout A-549 Cell Line | EDJ-KQ66500 | Human | 117248 | Details Get a Quote |
| GALNT15 Knockout HCT 116 Cell Line | EDJ-KQ74919 | Human | 117248 | Details Get a Quote |
